Publisher
Springer Berlin Heidelberg
Reference95 articles.
1. Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne I-M, Spooner A, Rain J, Rasi G (2014): Proactively managing the risk of marketed drugs: experience with the EMA pharmacovigilance risk assessment committee. Nat Rev Drug Discovery 13: 395–397
2. Arnadottir AH, Haajer-Ruskamp FM, Straus SMJ, Eichler HG, de Graeff PA, Mol PGM (2011): Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 72: 490–499
3. ASH Clinical News: The Geography of drug approvals. How can regulators look at the same data and get different results? Internet: https://www.ashclinicalnews.org/features/geography-drug-approvals (Zugriff: 14.08.2017)
4. Avorn J, Kesselheim AS (2015): The 21st century cures act – Will it take us back in time? N Engl J Med 372: 2473–2475
5. Baird LG, Banken R, Eichler HG, Kristensen FB, Lee DK, Lim JC, Lim R, Longson C, Pezalla E, Salmonson T, Samaha D, Tunis S, Woodcock J, Hirsch G (2014): Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther 96: 559–571
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献